PolyPid (NASDAQ:PYPD) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

PolyPid (NASDAQ:PYPD) announced its earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.03, FiscalAI reports.

Here are the key takeaways from PolyPid’s conference call:

• FDA accepted D-PLEX100’s NDA for filing with priority review and no filing-review issues identified; the PDUFA goal date is November 28, 2026.
• PolyPid signed an exclusive U.S. and Canadian commercialization agreement with Azurity, securing $30 million in upfront and near-term milestones, eligibility for more than $290 million in additional milestones, tiered royalties, and a transfer price on manufactured units.
• Azurity has begun launch preparations, including sales-force expansion, hospital contracting, medical affairs, and reimbursement efforts, with a commercial launch still expected in early 2027. The partnership will also fund label-expansion development in additional surgical indications.
• Management expects its cash resources, partnership proceeds, and potential future payments to fund operations into 2028, and said it has no immediate financing needs.
• PolyPid plans to submit D-PLEX100’s marketing authorization application to the European Medicines Agency in the third quarter of 2026 and is preparing for the FDA pre-approval manufacturing inspection; management reported productive regulatory discussions but approval remains subject to review.

PolyPid Price Performance

Shares of NASDAQ:PYPD traded down $0.10 during midday trading on Wednesday, reaching $4.63. The company had a trading volume of 171,936 shares, compared to its average volume of 127,516. The stock has a market capitalization of $88.35 million, a P/E ratio of -2.42 and a beta of 1.41. The stock’s fifty day moving average price is $4.73 and its 200-day moving average price is $4.57. PolyPid has a one year low of $3.06 and a one year high of $5.73.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PYPD. ADAR1 Capital Management LLC bought a new stake in shares of PolyPid in the 4th quarter worth about $451,000. XTX Topco Ltd lifted its position in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the last quarter. Jane Street Group LLC bought a new position in shares of PolyPid during the fourth quarter worth about $66,000. HighTower Advisors LLC bought a new position in shares of PolyPid during the fourth quarter worth about $44,000. Finally, BNP Paribas Financial Markets grew its stake in PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after purchasing an additional 3,500 shares in the last quarter. 26.47% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on PYPD. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a report on Tuesday, July 21st. Weiss Ratings raised PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Finally, Craig Hallum set a $12.00 price target on PolyPid in a report on Wednesday, July 22nd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.33.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.